Veterinarians and farmers across the globe have reached the landmark of protecting one billion pigs from the potentially devastating effects of Porcine Circovirus Disease (PCVD) using Ingelvac CircoFLEX®.
The vaccine, which was launched by Boehringer Ingelheim Animal Health in 2006, contributes to securing the pigs’ health as well as providing healthier pork for people to consume around the world.
Based on yearly sales volumes (in comparison to all other vaccines in animal health)*1, Ingelvac CircoFLEX® is the most successful animal vaccine of all time. The efficacy and safety of Ingelvac CircoFLEX®, which is a unique combination of Purified Circo Antigen (PCA®) and the adjuvant platform ImpranFLEX®, have established the brand globally as customers’ number one choice for vaccinating pigs against PCVD for several years*2.
PCVD is considered as being one of the most costly swine diseases – both from a herd health and an economic perspective. Prevention of PCVD and other diseases through vaccination reduces the need for antibiotics and leads to an improved quality of food for consumers worldwide.
Based on local and international market research data (data on file).
Local and international market research data 2008 - 2011; for 2012 based on Q1 – Q3.